Treatment Information

Back

Kidney (Renal) Cancer treatment details. Chemotherapy.

University of Chicago, Chicago, Illinois, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Chicago, Illinois
Treatments:ChemotherapyHospital:University of Chicago
Drugs:Journal:Link
Date:Sep 2006

Description:

Patients: This phase II study involved 60 patients with metastatic kidney cancer, four of which did not did not start the treatment. Forty-three were men and 13 were women, with ages ranging from 54 to 69 years. Seventy-nine percent had a prior nephrectomy and 75% had a prior systemic therapy (either chemotherapy or biologic).

Treatment: 56 patients received the chemotherapy drugs gemcitabine and capecitabine.

Toxicity: Grade 3 or 4 neutropenia occurred in 45% of patients, one with fever. Other grade 3 toxicities included cardiac ischemia, thrombosis, and a gastrointestinal bleed. One patient had an acute abdomen requiring bowel resection who subsequently died from a hemorrahagic cardiovascular event while receiving warfarin.

Results: The median survival time was 14.5 months. There were no complete responses, and the median time to disease progression was 5.6 months.

Correspondence: Walter M. Stadler, M.D.



Back